Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis
Conditions
Keywords
Biomarkers, COPD, IPF
Brief summary
Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges. This project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management. The expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.
Detailed description
The study adopts a prospective cohort design involving patients with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF), within which a nested, non-randomized interventional substudy on telemedicine monitoring of COPD patients is conducted. This approach combines the investigation of novel molecular, immunological, and genetic/epigenetic biomarkers for personalized medicine with a pragmatic evaluation of a telemonitoring intervention under real-world clinical practice conditions in COPD patients at high risk of exacerbation. The intervention includes home use of the MAIA telemonitoring platform, the FIRST oscillometry device (Restech), based on the Forced Oscillation Technique (FOT) for the assessment of respiratory mechanics, a smart inhaler (Plastiape RS01X) provided by the industrial partner Delim for monitoring adherence to inhaled therapy, and XearPro environmental sensors, supplied by XEarPro S.r.l., for the detection of atmospheric pollutants. Participants are initially enrolled and followed according to a purely observational approach. A subgroup of the cohort, identified on the basis of predefined clinical and/or operational criteria, is subsequently invited to participate in the interventional component of the study in a non-randomized manner. The effectiveness of the intervention will be assessed using a within-subject comparison, evaluating disease progression during the 12 months preceding enrolment in the interventional substudy and the 12 months following enrolment. This within-patient control design is considered more efficient than the inclusion of a randomized control group, particularly in light of the limited number of participants that can be pragmatically recruited. The remaining cohort members will continue standard follow-up to evaluate the natural course of their disease. Patients who provide informed consent to participate in the nested interventional substudy will receive detailed instructions on the correct use of the MAIA platform and its associated devices, as well as on the procedures and schedule for completing the study questionnaires. Participants will then be followed longitudinally, with follow-up assessments at 6 and 12 months. Withdrawal from the study (drop-out) will occur if the patient and/or caregiver becomes unable to continue the protocol-required activities, if there is non-compliance with the protocol timeline (defined as failure to meet two consecutive monthly deadlines), or if informed consent is withdrawn.
Interventions
OTHERIntegrated Precision Medicine Platform
Participants will undergo an integrated precision medicine intervention for inflammatory lung diseases, including multi-omics biomarker assessment, clinical and environmental monitoring, and telemedicine-supported follow-up. The intervention includes the collection of biological samples for biomarker profiling, assessment of indoor and outdoor environmental exposures, and continuous monitoring of clinical and environmental parameters. Where applicable, participants will receive a precision inhalation medical device designed to optimize drug delivery. Data from biomarker analyses, monitoring devices, and the telemedicine platform will be integrated to support personalized disease management and the early identification of disease exacerbations.
Sponsors
Fondazione Don Carlo Gnocchi ETS
Programma Regionale FESR - Regione Lombardia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults aged 18 years or older. * Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines. * Ability and willingness to provide written informed consent. * Willingness to provide blood and saliva samples for biomarker analyses. * Willingness and ability to undergo clinical assessments and scheduled follow-up visits. * Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools.
Exclusion criteria
* Age younger than 18 years. * Inability or unwillingness to provide written informed consent. * Inability to comply with study procedures or scheduled follow-up. * Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results. * Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Innate immunity | Baseline to Month 27 | monocytes, macrophages, neutrophils, dendritic cells, NLRP-3 inflammasome (for all: % of cells) |
| Adaptive immunity in blood | baseline to month 27 | caspase 1-5, CTLA-4, TGF-b, PD-1, PDL-1, PDL-2, Galectin9, LAG-3, TIM-3, VISTA, TIGIT, IL-1b, IL-6, IL-10, IL-13, IL-17, IL-18, IL-21, IL-22, IL-23, IL-35 (for all: ng/ml) |
| Extracellular matrix proteins from saliva and serum | baseline to month 27 | Desmosine/isodesmosine, VEGF (for all: ng/ml) |
| serum microRNAs | baseline to month 27 | serum microRNAs by miRNOme analyses (copies/ng) |
| Genetic polymorphisms | baseline to month 27 | KIR; HLA-Cw, VDR, GC1, IL-1β, IL-1Ra, IL-6, IL-10, IL-13, IL-18, TGF-β1, TNF-α polymorphisms (for all: presence or absence |
| Salivary Raman spectral fingerprint | baseline to month 27 | Disease-specific Raman spectral fingerprint obtained from saliva samples using a standardized patented Raman spectroscopy protocol to identify COPD and IPF patient subpopulations. |
| Forced Expiratory Volume in 1 second | baseline to month 27 | Forced Expiratory Volume in 1 second (FEV1) (%) |
| VC | baseline to month 27 | Vital Capacity (VC) (%) |
| Total Lung Capacity | baseline to month 27 | Total Lung Capacity (TLC) (%) |
| Inspiratory Capacity | baseline to month 27 | Inspiratory Capacity (IC) (%) |
| Expiratory Reserve Volume | baseline to month 27 | Expiratory Reserve Volume (ERV) (%) |
| Residual Volume | baseline to month 27 | Residual Volume (RV) (%) |
| Diffusing Capacity of the Lung for Carbon Monoxide / Alveolar Volume | baseline to month 27 | Diffusing Capacity of the Lung for Carbon Monoxide / Alveolar Volume (DLCO/AV) (%) |
| Blood gas analysis - PaO2 | baseline to month 27 | PaO2 (mmHg) |
| Blood gas analysis - PaCO2 | baseline to month 27 | PaCO2 (mmHg) |
| Test 6 minute walk | baseline to month 27 | Test 6 minute walk (metres) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Moderate or Severe Exacerbations | Baseline to Month 27 | Number of Moderate or Severe Exacerbations (absolute number) |
| COPD Assessment Test (CAT) Score | baseline to month 27 | COPD Assessment Test (CAT) Score (points) |
| Modified Medical Research Council (mMRC) Dyspnea Scale Score | baseline to month 27 | Modified Medical Research Council (mMRC) Dyspnea Scale Score (points) |
| Time to first moderate or severe exacerbation | baseline to month 27 | Time to first moderate or severe exacerbation (days) |
| COPD Assessment Test (CAT) | baseline to month 27 | COPD Assessment Test (CAT) (score) |
| Pulmonary rehabilitation within the previous 12 months | baseline to month 27 | Pulmonary rehabilitation within the previous 12 months (absolute number) |
| Dyspnea severity | baseline to month 27 | Modified Medical Research Council (mMRC) Dyspnea Scale (score) |
Contacts
CONTACTMario Clerici, MD
CONTACTSimone Agostini, PhD
PRINCIPAL_INVESTIGATORLuca Bianchi
Fondazione Don Gnocchi ETS
Outcome results
None listed